Bloomberg Businessweek examines how ongoing trade negotiations related to the Trans-Pacific Partnership could affect access to quality low-cost medications, including antiretrovirals, in low- and middle-income countries. "Protecting the patents of drug makers ... as part of the Trans-Pacific Partnership has drawn criticism from groups such as Doctors Without Borders and Public Citizen," and "[t]he proposed accord has also spurred calls from U.S. lawmakers for greater transparency about the negotiations," the news service writes. "The multilateral talks, the main accord being pursued by President Barack Obama's administration, ... began with Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam [and] may expand after the parties invited Canada and Mexico," the news service notes.